Skip to main content
Erschienen in: La radiologia medica 4/2019

01.04.2019 | RADIOTHERAPY

Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy

verfasst von: Barbara Alicja Jereczek-Fossa, Barbara Bortolato, Marianna Alessandra Gerardi, Samantha Dicuonzo, Virginia Maria Arienti, Stefania Berlinghieri, Stefano Bracelli, Michela Buglione, Mariangela Caputo, Gianpiero Catalano, Luigi Franco Cazzaniga, Luigi De Cicco, Nadia Di Muzio, Francesco Romeo Filippone, Andrei Fodor, Davide Franceschini, Paolo Frata, Stefania Gottardo, Giovanni Battista Ivaldi, Antonio Laudati, Stefano Maria Magrini, Elisa Mantero, Ilaria Meaglia, Sara Morlino, Mauro Palazzi, Fabio Piccoli, Paola Romanelli, Marta Scorsetti, Flavia Serafini, Luciano Scandolaro, Riccardo Valdagni, Roberto Orecchia, Paolo Antognoni, the Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L)

Erschienen in: La radiologia medica | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Aims

To evaluate the use of radiotherapy (RT) for oligometastatic cancer (OMC) among radiation oncologists in Lombardy, Italy.

Methods and study design

A survey with 12 items regarding data of 2016 was sent to all 34 Lombardy RT centers. The survey included six general items and six specific items regarding patient/disease/treatment characteristics.

Results

Thirteen centers answered the survey (38%). All centers responded to general items and 12 centers submitted patient/disease/treatment data. General items The majority of centers (8/13) consider OMC if metastases number is less than 5. The most commonly prescribed dose/fraction is 5–10 Gy (8/13) using schedules of 3–5 fractions (11/13). Patient data items A total of 15.681 patients were treated in 2016 with external beam RT in 12 responding centers, and 1.087 patients were treated for OMC (7%). Primary tumor included lung, prostate, breast, colorectal and other malignancies in 33%, 21%, 12%, 9% and 25% of all OMC patients, respectively. Brain, lymph node, lung, bone, liver and others were the most common treated sites (24%, 24%, 22%, 17%, 8% and 5%, respectively). One and more than one metastasis were treated in 75 and 25% of patients, respectively. The vast majority of patients (95%) were treated with image-guided intensity-modulated RT or stereotactic RT.

Conclusions

Seven percent of all RT patients in Lombardy are treated for OMC. Extreme hypofractionation and high-precision RT are commonly employed. The initiative of multicenter and multidisciplinary collaboration has been undertaken in order to prepare the platform for prospective and/or observational studies in OMC.
Literatur
2.
Zurück zum Zitat Franklin JM, Sharma RA, Harris AL, Gleeson FV (2016) Imaging oligometastatic cancer before local treatment. Lancet Oncol. 17(9):e406–e414CrossRefPubMed Franklin JM, Sharma RA, Harris AL, Gleeson FV (2016) Imaging oligometastatic cancer before local treatment. Lancet Oncol. 17(9):e406–e414CrossRefPubMed
4.
Zurück zum Zitat Zhao Y, Li J, Li C, Fan J, Liu L (2017) Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta-analysis. Int J Surg 41:70–77CrossRefPubMed Zhao Y, Li J, Li C, Fan J, Liu L (2017) Prognostic factors for overall survival after lung metastasectomy in renal cell cancer patients: a systematic review and meta-analysis. Int J Surg 41:70–77CrossRefPubMed
5.
Zurück zum Zitat Tonyali S, Yazici S (2016) Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies? Int Urol Nephrol 48(5):671–680CrossRefPubMed Tonyali S, Yazici S (2016) Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies? Int Urol Nephrol 48(5):671–680CrossRefPubMed
6.
Zurück zum Zitat Moorcraft SY, Ladas G, Bowcock A, Chau I (2016) Management of resectable colorectal lung metastases. Clin Exp Metastasis 33(3):285–296CrossRefPubMed Moorcraft SY, Ladas G, Bowcock A, Chau I (2016) Management of resectable colorectal lung metastases. Clin Exp Metastasis 33(3):285–296CrossRefPubMed
7.
Zurück zum Zitat Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863CrossRefPubMed Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863CrossRefPubMed
8.
Zurück zum Zitat Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15(4):e623–e632CrossRefPubMed Jereczek-Fossa BA, Fanetti G, Fodor C, Ciardo D, Santoro L, Francia CM (2017) Salvage stereotactic body radiotherapy for isolated lymph node recurrent prostate cancer: single institution series of 94 consecutive patients and 124 lymph nodes. Clin Genitourin Cancer 15(4):e623–e632CrossRefPubMed
9.
Zurück zum Zitat Jereczek-Fossa BA, Ronchi S, Orecchia R (2015) Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother 20(6):472–483CrossRefPubMed Jereczek-Fossa BA, Ronchi S, Orecchia R (2015) Is stereotactic body radiotherapy (SBRT) in lymph node oligometastatic patients feasible and effective? Rep Pract Oncol Radiother 20(6):472–483CrossRefPubMed
10.
Zurück zum Zitat Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel K et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 17:361CrossRefPubMedPubMedCentral Habl G, Straube C, Schiller K, Duma MN, Oechsner M, Kessel K et al (2017) Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer 17:361CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11:27–32CrossRefPubMed Berkovic P, De Meerleer G, Delrue L et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11:27–32CrossRefPubMed
12.
Zurück zum Zitat Yeung R, Hamm J, Liu M, Schellenberg D (2017) Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 12:105CrossRefPubMedPubMedCentral Yeung R, Hamm J, Liu M, Schellenberg D (2017) Institutional analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lymph node metastases. Radiat Oncol 12:105CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116(12):1520–1525CrossRefPubMedPubMedCentral Triggiani L, Alongi F, Buglione M, Detti B, Santoni R, Bruni A et al (2017) Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study. Br J Cancer 116(12):1520–1525CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Redmond KJ, Lo SS, Dagan R, Poon I, Foote MC, Erler D et al (2017) A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. Future Oncol. 13(12):1081–1089CrossRefPubMed Redmond KJ, Lo SS, Dagan R, Poon I, Foote MC, Erler D et al (2017) A multinational report of technical factors on stereotactic body radiotherapy for oligometastases. Future Oncol. 13(12):1081–1089CrossRefPubMed
15.
Zurück zum Zitat Ricardi U, Badellino S, Filippi AR (2016) Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res 8. pii: rrw006 Ricardi U, Badellino S, Filippi AR (2016) Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res 8. pii: rrw006
16.
Zurück zum Zitat Orecchia R, Surgo A, Muto M, Ferrari A, Piperno G, Gerardi MA et al (2016) VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions. Ecancermedicalscience 29(10):677 Orecchia R, Surgo A, Muto M, Ferrari A, Piperno G, Gerardi MA et al (2016) VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions. Ecancermedicalscience 29(10):677
17.
Zurück zum Zitat Scorsetti M, Franceschini D, De Rose F, Comito T, Franzese C, Masci G et al (2017) The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Rep Pract Oncol Radiother 22(2):163–169CrossRefPubMed Scorsetti M, Franceschini D, De Rose F, Comito T, Franzese C, Masci G et al (2017) The role of SBRT in oligometastatic patients with liver metastases from breast cancer. Rep Pract Oncol Radiother 22(2):163–169CrossRefPubMed
18.
Zurück zum Zitat Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F et al (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol 35(1):45–49CrossRefPubMed Ingrosso G, Trippa F, Maranzano E, Carosi A, Ponti E, Arcidiacono F et al (2017) Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience. World J Urol 35(1):45–49CrossRefPubMed
19.
Zurück zum Zitat Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF (2017) Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer 16(1):58–64CrossRefPubMed Agolli L, Bracci S, Nicosia L, Valeriani M, De Sanctis V, Osti MF (2017) Lung metastases treated with stereotactic ablative radiation therapy in oligometastatic colorectal cancer patients: outcomes and prognostic factors after long-term follow-up. Clin Colorectal Cancer 16(1):58–64CrossRefPubMed
20.
Zurück zum Zitat Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R (2014) Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 37(3):227–233CrossRefPubMed Jereczek-Fossa BA, Piperno G, Ronchi S, Catalano G, Fodor C, Cambria R (2014) Linac-based stereotactic body radiotherapy for oligometastatic patients with single abdominal lymph node recurrent cancer. Am J Clin Oncol 37(3):227–233CrossRefPubMed
21.
Zurück zum Zitat Palazzi M et al (2017) Equipment, staffing and provision of Radiotherapy in Lombardy, Italy: results of three sequential “snapshot” surveys performed between 2012 and 2016. Tumori, AIRO, Thousand Oaks Palazzi M et al (2017) Equipment, staffing and provision of Radiotherapy in Lombardy, Italy: results of three sequential “snapshot” surveys performed between 2012 and 2016. Tumori, AIRO, Thousand Oaks
23.
Zurück zum Zitat Jereczek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P et al (2015) Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. Tumori 101(2):174–178CrossRefPubMed Jereczek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P et al (2015) Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. Tumori 101(2):174–178CrossRefPubMed
25.
Zurück zum Zitat Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R et al (2017) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178–211CrossRefPubMed Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R et al (2017) Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 73:178–211CrossRefPubMed
26.
Zurück zum Zitat Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS et al (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121(1):98–102CrossRefPubMed Sridharan S, Steigler A, Spry NA, Joseph D, Lamb DS et al (2016) Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol 121(1):98–102CrossRefPubMed
27.
Zurück zum Zitat Cho JH, Kim S, Namgung M, Choi YS, Kim HK, Zo JI, Shim YM, Kim J (2015) The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol. 25(13):222CrossRef Cho JH, Kim S, Namgung M, Choi YS, Kim HK, Zo JI, Shim YM, Kim J (2015) The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol. 25(13):222CrossRef
28.
Zurück zum Zitat Pougnet I, Jaegle E, Garcia R, Tessier F, Faivre JC, Louvel G et al (2017) Spinal stereotactic body radiotherapy: French assessment in 2016. Cancer Radiother 21(4):276–285CrossRefPubMed Pougnet I, Jaegle E, Garcia R, Tessier F, Faivre JC, Louvel G et al (2017) Spinal stereotactic body radiotherapy: French assessment in 2016. Cancer Radiother 21(4):276–285CrossRefPubMed
30.
Zurück zum Zitat Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C et al (2009) Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 93:14–17CrossRefPubMed Jereczek-Fossa BA, Fariselli L, Beltramo G, Catalano G, Serafini F, Garibaldi C et al (2009) Linac-based or robotic image-guided stereotactic radiotherapy for isolated lymph node recurrent prostate cancer. Radiother Oncol 93:14–17CrossRefPubMed
31.
Zurück zum Zitat Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37CrossRefPubMed Kroeze SG, Fritz C, Hoyer M, Lo SS, Ricardi U, Sahgal A et al (2017) Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: a systematic review. Cancer Treat Rev 53:25–37CrossRefPubMed
32.
Zurück zum Zitat Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):5047–5101CrossRef Benedict SH, Yenice KM, Followill D et al (2010) Stereotactic body radiation therapy: the report of AAPM task group 101. Med Phys 37(8):5047–5101CrossRef
33.
Zurück zum Zitat Flickinger JC, Niranjan A (2013) Stereotactic radiosurgery and radiotherapy. In: Halperin EC, Wazer DE, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology. Lippincott Williams and Wilkins, Philadelphia, pp 351–361 Flickinger JC, Niranjan A (2013) Stereotactic radiosurgery and radiotherapy. In: Halperin EC, Wazer DE, Perez CA, Brady LW (eds) Perez and Brady’s principles and practice of radiation oncology. Lippincott Williams and Wilkins, Philadelphia, pp 351–361
34.
Zurück zum Zitat Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88:254–262CrossRefPubMedPubMedCentral Brown JM, Carlson DJ, Brenner DJ (2014) The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys 88:254–262CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Espenel S, Vallard A, Rancoule C, Garcia MA, Guy JB, Chargari C et al (2017) Melanoma: last call for radiotherapy. Crit Rev Oncol Hematol 110:13–19CrossRefPubMed Espenel S, Vallard A, Rancoule C, Garcia MA, Guy JB, Chargari C et al (2017) Melanoma: last call for radiotherapy. Crit Rev Oncol Hematol 110:13–19CrossRefPubMed
36.
Zurück zum Zitat Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES et al (2017) A phase II randomized trial of observation versus stereotactic ablative RadiatIon for zLigometastatic prostate CancEr (ORIOLE). BMC Cancer 17:453CrossRefPubMedPubMedCentral Radwan N, Phillips R, Ross A, Rowe SP, Gorin MA, Antonarakis ES et al (2017) A phase II randomized trial of observation versus stereotactic ablative RadiatIon for zLigometastatic prostate CancEr (ORIOLE). BMC Cancer 17:453CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Alongi F, Arcangeli S, Triggiani L, Mazzola R, Buglione di Monale E, Bastia M, Fersino S et al (2017) On the behalf of Italian Association of Radiation Oncology [AIRO]. Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease. Crit Rev Oncol Hematol 117:48–56CrossRefPubMed Alongi F, Arcangeli S, Triggiani L, Mazzola R, Buglione di Monale E, Bastia M, Fersino S et al (2017) On the behalf of Italian Association of Radiation Oncology [AIRO]. Stereotactic ablative radiation therapy in renal cell carcinoma: from oligometastatic to localized disease. Crit Rev Oncol Hematol 117:48–56CrossRefPubMed
38.
Zurück zum Zitat Kwint M, Walraven I, Burgers S, Hartemink K, Klomp H, Knegjens J et al (2017) Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Lung Cancer 112:134–139CrossRefPubMed Kwint M, Walraven I, Burgers S, Hartemink K, Klomp H, Knegjens J et al (2017) Outcome of radical local treatment of non-small cell lung cancer patients with synchronous oligometastases. Lung Cancer 112:134–139CrossRefPubMed
39.
Zurück zum Zitat Franzese C, Fogliata A, Comito T, Tozzi A, Iftode C, Clerici E et al (2017) Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol 90(1079):20170422CrossRefPubMedPubMedCentral Franzese C, Fogliata A, Comito T, Tozzi A, Iftode C, Clerici E et al (2017) Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis. Br J Radiol 90(1079):20170422CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Alongi F, Fogliata A, Clerici E et al (2012) Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 5(7):204CrossRef Alongi F, Fogliata A, Clerici E et al (2012) Volumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients. Radiat Oncol 5(7):204CrossRef
41.
Zurück zum Zitat Wild AT, Yamada Y (2017) Treatment options in oligometastatic disease: stereotactic body radiation therapy—focus on colorectal Cancer. Visc Med. 33(1):54–61CrossRefPubMedPubMedCentral Wild AT, Yamada Y (2017) Treatment options in oligometastatic disease: stereotactic body radiation therapy—focus on colorectal Cancer. Visc Med. 33(1):54–61CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Weichselbaum RR, Liang H, Deng L, Fu YX (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365–379CrossRefPubMed Weichselbaum RR, Liang H, Deng L, Fu YX (2017) Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol 14(6):365–379CrossRefPubMed
44.
Zurück zum Zitat Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682CrossRefPubMedPubMedCentral Gomez DR, Blumenschein GR Jr, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17(12):1672–1682CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS et al (2017) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 24:e173501 Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS et al (2017) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 24:e173501
Metadaten
Titel
Radiotherapy for oligometastatic cancer: a survey among radiation oncologists of Lombardy (AIRO-Lombardy), Italy
verfasst von
Barbara Alicja Jereczek-Fossa
Barbara Bortolato
Marianna Alessandra Gerardi
Samantha Dicuonzo
Virginia Maria Arienti
Stefania Berlinghieri
Stefano Bracelli
Michela Buglione
Mariangela Caputo
Gianpiero Catalano
Luigi Franco Cazzaniga
Luigi De Cicco
Nadia Di Muzio
Francesco Romeo Filippone
Andrei Fodor
Davide Franceschini
Paolo Frata
Stefania Gottardo
Giovanni Battista Ivaldi
Antonio Laudati
Stefano Maria Magrini
Elisa Mantero
Ilaria Meaglia
Sara Morlino
Mauro Palazzi
Fabio Piccoli
Paola Romanelli
Marta Scorsetti
Flavia Serafini
Luciano Scandolaro
Riccardo Valdagni
Roberto Orecchia
Paolo Antognoni
the Lombardy Section of the Italian Society of Oncological Radiotherapy (Associazione Italiana di Radioterapia Oncologica-Lombardia, AIRO-L)
Publikationsdatum
01.04.2019
Verlag
Springer Milan
Erschienen in
La radiologia medica / Ausgabe 4/2019
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-018-0972-6

Weitere Artikel der Ausgabe 4/2019

La radiologia medica 4/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.